Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Plain-language summary
This Phase 2 trial is evaluating Mogamulizumab, DA-EPOCH Protocol, and other medications as a treatment for people newly diagnosed with adult T-cell leukemia/lymphoma. The study measures how well this treatment works and monitors for side effects. It is available at 2 US locations.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Mogamulizumab (DRUG): Mogamulizumab is a defucosylated, humanized, monoclonal antibody (Mab) with enhanced antibody dependent cellular cytotoxicity that binds to CCR4. The lack of fucose results in the antibody eliciting more potent ADCC than conventionally produced antibodies. Mogamulizumab is devoid of complement dependent cytotoxicity. CC Chemokine receptor 4 is over expressed on the surfaces of cells comprising several T-cell malignancies such as peripheral T-cell lymphoma (PTCL) and CTCL and is a potential target for anti-neoplastic therapy in these disorders. | DA-EPOCH Protocol (DRUG): EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma. | CHOEP protocol (DRUG): CHOEP is an intensive chemotherapy intended for treatment of aggressive t-cell lymphoma.
- Drugs / treatments
- Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details